Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis life sciences firm Seradyn Inc. notified the Indiana Department of Workforce Development yesterday that it would close at the end of the year, leaving 114 employees out of work.
Seradyn, part of Massachusetts-based Thermo Fisher Scientific, develops laboratory methods called “assays” that use antibodies to measure drug concentrations in the bloodstream.
The company, located at 7998 Georgetown Road, did not provide a reason for the closing in its notice to state officials. A Seradyn official referred questions to the parent company. A Thermo Fisher Scientific official said the company would issue a statement later today.
In the past 10 years, Seradyn has developed at least 15 such products used in the management of epilepsy, transplantation and seizures.
In 2006, Seradyn became the first company to introduce assays that measure the concentrations of antiepileptic drugs lamotrigine and zonisanide. The two are newer epilepsy pharmaceuticals that have proven effective in controlling seizures.
Just last year, Seradyn General Manager Mark Roberts told IBJ that Seradyn planned to expand the 55,000 square feet it occupies on the northwest side and grow its number of employees.
In 2008, the company ranked as the city’s eighth-largest biotechnology and pharmaceutical company, in terms of employees, according to IBJ statistics.
But the company had gone through a slew of owners in the 30-plus years since its inception. Seradyn’s roots date to the mid-1970s, when the former Dow Chemical Co. established the Dow Diagnostics division to produce clinical assays.
Please enable JavaScript to view this content.